Literature DB >> 16642228

Reasons for coming to hospital after treatment for community-acquired pneumonia on an ambulatory basis.

Mohammedreza Shariatzadeh1, Thomas J Marrie.   

Abstract

BACKGROUND: Most patients with community-acquired pneumonia (CAP) are treated on an ambulatory basis.
OBJECTIVE: To evaluate the reasons for presentation to hospital after treatment for CAP on an ambulatory basis.
METHODS: The study, conducted in five hospitals in the Capital Health Region (Edmonton, Alberta), enrolled adult patients aged 17 years or older who presented with a history of having been diagnosed and treated for pneumonia within the previous month. A current diagnosis of pneumonia was based on two or more symptoms or signs of CAP, plus radiographic evidence of pneumonia.
RESULTS: Seventy-five (77.3%) of the 97 patients who met the inclusion criteria had CAP, and 22 (22.7%) patients presented with a noninfectious illness. Of the patients with CAP, 25 (33.3%) met the study criteria for worsening of a comorbid illness, 23 (30.7%) had clinical failure, 16 (21.3%) had microbiological failure, six (8.0%) were noncompliant, four (5.3%) had failure of expectations and one (1.3%) had adverse effects of antimicrobial therapy.
CONCLUSIONS: Underlying diseases, exacerbations of comorbidities and complications of CAP, as well as confounders such as unusual infections and noninfectious conditions that mimic CAP, are all reasons for presenting to hospital after treatment for CAP in an ambulatory setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642228      PMCID: PMC2539019          DOI: 10.1155/2006/759694

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  27 in total

1.  Prospective study of community-acquired pneumonia of bacterial etiology in adults.

Authors:  N Sopena; M Sabrià; M L Pedro-Botet; J M Manterola; L Matas; J Domínguez; J M Modol; P Tudela; V Ausina; M Foz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-12       Impact factor: 3.267

2.  Pneumocystis carinii pneumonia as the first presentation of HIV infection in patients older than fifty.

Authors:  V Jedlovsky; J K Fleischman
Journal:  AIDS Patient Care STDS       Date:  2000-05       Impact factor: 5.078

3.  BOOP: an important cause of migratory pulmonary infiltrates?

Authors:  T E King
Journal:  Eur Respir J       Date:  1995-02       Impact factor: 16.671

4.  The cost of treating community-acquired pneumonia.

Authors:  M S Niederman; J S McCombs; A N Unger; A Kumar; R Popovian
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

5.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors:  D K Chen; A McGeer; J C de Azavedo; D E Low
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

6.  Patients hospitalized after initial outpatient treatment for community-acquired pneumonia.

Authors:  M F Minogue; C M Coley; M J Fine; T J Marrie; W N Kapoor; D E Singer
Journal:  Ann Emerg Med       Date:  1998-03       Impact factor: 5.721

7.  Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.

Authors:  Christine Malcolm; Thomas J Marrie
Journal:  Arch Intern Med       Date:  2003-04-14

Review 8.  Noninfectious pulmonary diseases masquerading as community-acquired pneumonia.

Authors:  T J Gross; A D Chavis; J P Lynch
Journal:  Clin Chest Med       Date:  1991-06       Impact factor: 2.878

Review 9.  Collagen vascular diseases.

Authors:  D E Corley; R H Winterbauer
Journal:  Semin Respir Infect       Date:  1995-06

Review 10.  Neoplastic mimics of pneumonia.

Authors:  K R Casey
Journal:  Semin Respir Infect       Date:  1995-09
View more
  1 in total

Review 1.  Strength-training exercise in dysphagia rehabilitation: principles, procedures, and directions for future research.

Authors:  Lori M Burkhead; Christine M Sapienza; John C Rosenbek
Journal:  Dysphagia       Date:  2007-04-25       Impact factor: 3.438

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.